Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
Provectus (OTCQB: PVCT) announced the successful development of a second halogenated xanthene (HX) molecule, enhancing its existing pipeline that includes the clinical-stage rose bengal sodium (RBS). The newly synthesized HX, with a complex molecular name, expands Provectus' proprietary intellectual property portfolio. The company adheres to Quality-by-Design (QbD) principles and cGMP guidelines for its products. Vice Chair Dominic Rodrigues expressed optimism about the potential of this new small molecule in drug development, aiming for it to become a viable drug candidate.
- Successful development of a second halogenated xanthene molecule expands the product pipeline.
- Adherence to Quality-by-Design (QbD) principles indicates a focus on high manufacturing standards.
- Expansion of intellectual property portfolio enhances potential for future innovations.
- None.
KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS).
The molecular name of the newly synthesized HX is 4,5,6,7-tetrabromo-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenz- ofuran-1,9'-xanthen]-3-one.
Provectus’ intellectual property estate comprises an entire class of proprietary, related HX molecules that are proprietarily-synthesized using Quality-by-Design principles (QbD) under current Good Manufacturing Practice (cGMP) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors said, “Different permutations and combinations of halogen atoms on the backbone of this molecular class convey different biological, chemical, and/or physical properties to each class member. We are excited to have produced a new halogenated xanthene, further expanding our medical science platform. We look forward to developing this small molecule into a viable Provectus drug product candidate.”
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Provectus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.
###
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
FAQ
What is the new molecule developed by Provectus PVCT?
What is the significance of the new halogenated xanthene for Provectus PVCT?
How does Provectus ensure quality in its drug manufacturing?
What is the lead molecule of Provectus PVCT?
What future developments can be expected from Provectus PVCT?
